Neoplasms

All Conditions

Digestive System Diseases

Skin and Connective Tissue Diseases

Rare Diseases

Carcinoma

Stomach Neoplasms

Breast Neoplasms

Esophageal Neoplasms

Carcinoma, Adenoid Cystic

Stomach Cancer

Esophageal Cancer

Adenoid Cystic Carcinoma

All Drugs and Chemicals

Antineoplastic Agents

Antibodies

Antibodies, Monoclonal

Trastuzumab

Immunomodulating Agents

Immunoglobulins

Antineoplastic Agents, Immunological

Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)

ACTR T Cell Product

Glen Weiss, MD

This is a Phase 1, open-label, multi-center study to assess safety and determine the recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination with trastuzumab, following lymphodepleting chemotherapy in subjects with HER2-positive advanced malignancies.

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies

Review of DLTs, maximum tolerated dose (MTD), incidence and severity of AEs and clinically significant abnormalities of laboratory values

Levels of inflammatory markers, cytokines/chemokines in blood

trastuzumab serum concentration, Area Under the Curve (AUC), trough levels

Cogent Biosciences, Inc.

Blood and Lymph Conditions

Immune System Diseases

Lymphoma

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

B-cell Lymphoma

Antirheumatic Agents

Rituximab

Immunologic Factors

ACTR087

rituximab

Jessica Sachs, MD

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and efficacy of an autologous T-cell product expressing ACTR in combination with rituximab in subjects with refractory or relapsed CD20+ B-cell lymphoma.

Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma

Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Blood samples will be collected and analyzed for the presence of T-cells which express antibody coupled T-cell receptors, using flow cytometry and qPCR

Heart and Blood Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

B-cell maturation antigen (BCMA)-directed antibody

SEA-BCMA

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in combination with SEA-BCMA (a monoclonal antibody) in subjects with relapsed or refractory Multiple Myeloma.

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Composite outcome measure assessed by committee review of dose limiting toxicities (DLTs), incidence and severity of AEs and clinically significant abnormalities of laboratory values

Review of DLTs, Maximum tolerated contour (MTC), incidence and severity of AEs and clinically significant abnormalities of laboratory values

Review of all TEAEs, including incidence and severity of AEs, DLTs and clinically significant abnormalities of laboratory values

Levels of inflammatory markers, cytokines/chemokines

Seagen Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers	NCT03680560	Solid Tumor HER-2 Protein O...	ACTR T Cell Pro... Trastuzumab	18 Years - 75 Years	Cogent Biosciences, Inc.
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma	NCT02776813	Lymphoma	ACTR087 rituximab	18 Years - 75 Years	Cogent Biosciences, Inc.
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma	NCT03266692	Multiple Myelom... Multiple Myelom... Refractory Mult...	ACTR087 SEA-BCMA	18 Years - 80 Years	Cogent Biosciences, Inc.
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma	NCT02776813	Lymphoma	ACTR087 rituximab	18 Years - 75 Years	Cogent Biosciences, Inc.

Spots Global Cancer Trial Database for actr087

Every month we try and update this database with for actr087 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for actr087

Every month we try and update this database with for actr087 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for actr087 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.